Compare
Lifevantage Corp vs Stoke Therapeutics, Inc. vs Maravai Lifesciences Holdings, Inc. vs Cryoport, Inc.
| Latest fiscal year | Lifevantage Corp LFVN | Stoke Therapeutics, Inc. STOK | Maravai Lifesciences Holdings, Inc. MRVI | Cryoport, Inc. CYRX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $182.59M | $184.42M | $185.74M | $176.18M |
| Revenue growth (YoY) | -20.1% | +404.5% | -28.3% | +12.4% |
| Gross margin | 77.6% | n/a | 18.3% | 47.1% |
| Operating margin | 3.3% | -11.2% | -115.9% | -20.9% |
| Net margin | 2.8% | -3.7% | -70.4% | 44.4% |
| Net income | $5.07M | -$6.88M | -$130.77M | $78.30M |
| EPS (Diluted) | $0.40 | -$0.12 | -$0.90 | $1.40 |
| Operating cash flow | $10.24M | $45.59M | -$57.57M | -$8.58M |
| Free cash flow | $6.67M | $44.91M | -$70.72M | -$25.02M |
| Cash & equivalents | n/a | $84.22M | $216.89M | $250.49M |
| Total assets | $62.11M | $418.43M | $770.58M | $764.99M |
| Total liabilities | $28.52M | $65.98M | $397.87M | $262.35M |
| Shareholders' equity | $33.59M | $352.46M | $212.38M | $502.64M |
| Return on year-end equity | 15.1% | -2.0% | -61.6% | 15.6% |
| Shares outstanding | 12.52M | 58.92M | n/a | 49.85M |
Revenue, most recent five fiscal years
| Fiscal year | Lifevantage Corp | Stoke Therapeutics, Inc. | Maravai Lifesciences Holdings, Inc. | Cryoport, Inc. |
|---|---|---|---|---|
| Latest | $182.59M Ended 2026-06-30 | $184.42M Ended 2025-12-31 | $185.74M Ended 2025-12-31 | $176.18M Ended 2025-12-31 |
| 1 year earlier | $228.53M Ended 2025-06-30 | $36.55M Ended 2024-12-31 | $259.19M Ended 2024-12-31 | $156.77M Ended 2024-12-31 |
| 2 years earlier | $200.16M Ended 2024-06-30 | $8.78M Ended 2023-12-31 | $288.94M Ended 2023-12-31 | $168.66M Ended 2023-12-31 |
| 3 years earlier | $213.40M Ended 2023-06-30 | $12.40M Ended 2022-12-31 | $883.00M Ended 2022-12-31 | $237.28M Ended 2022-12-31 |
| 4 years earlier | $206.36M Ended 2022-06-30 | n/a | $799.24M Ended 2021-12-31 | $222.61M Ended 2021-12-31 |